APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs of UDCA

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Drugs of UDCA Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025190 pages

Choose your research edition.

Industry ResearchDrugs of UDCA Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs of UDCA Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Drugs of UDCA Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs of UDCA Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs of UDCA Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Drugs of UDCA market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Drugs of UDCA is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs of UDCA is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs of UDCA is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Drugs of UDCA is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Drugs of UDCA include Teva, Shanghai Pharma, Mylan, Mitsubishi Tanabe Pharma, Lannett, Impax, Grindeks, Epic Pharma and Dr. Falk Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Drugs of UDCA market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs of UDCA and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs of UDCA sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs of UDCA market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs of UDCA Segment by Company

Teva

Shanghai Pharma

Mylan

Mitsubishi Tanabe Pharma

Lannett

Impax

Grindeks

Epic Pharma

Dr. Falk Pharma

Daewoong Pharmaceutical

Bruschettini

Drugs of UDCA Segment by Type

Capsule

Tablet

Drugs of UDCA Segment by Application

Hepatopathy

Gallstone

Biliary Disease

Other

Drugs of UDCA Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs of UDCA market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs of UDCA and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs of UDCA.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs of UDCA market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Drugs of UDCA manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Drugs of UDCA in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Drugs of UDCA in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Drugs of UDCA Industry Trends Table 2. Drugs of UDCA Industry Drivers Table 3. Drugs of UDCA Industry Opportunities and Challenges Table 4. Drugs of UDCA Industry Restraints Table 5. Global Drugs of UDCA Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Drugs of UDCA Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Drugs of UDCA Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Drugs of UDCA Sales Market Share by Manufacturers Table 9. Global Drugs of UDCA Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Drugs of UDCA Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Drugs of UDCA Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Drugs of UDCA Manufacturers, Product Type & Application Table 13. Global Drugs of UDCA Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Drugs of UDCA by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Capsule Table 17. Major Manufacturers of Tablet Table 18. Global Drugs of UDCA Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Drugs of UDCA Sales by Type (2021-2026) & (k units) Table 20. Global Drugs of UDCA Sales by Type (2027-2032) & (k units) Table 21. Global Drugs of UDCA Sales Market Share by Type (2021-2026) Table 22. Global Drugs of UDCA Sales Market Share by Type (2027-2032) Table 23. Global Drugs of UDCA Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Drugs of UDCA Revenue by Type (2021-2026) & (k units) Table 25. Global Drugs of UDCA Revenue by Type (2027-2032) & (k units) Table 26. Global Drugs of UDCA Revenue Market Share by Type (2021-2026) Table 27. Global Drugs of UDCA Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hepatopathy Table 29. Major Manufacturers of Gallstone Table 30. Major Manufacturers of Biliary Disease Table 31. Major Manufacturers of Other Table 32. Global Drugs of UDCA Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Drugs of UDCA Sales by Application (2021-2026) & (k units) Table 34. Global Drugs of UDCA Sales by Application (2027-2032) & (k units) Table 35. Global Drugs of UDCA Sales Market Share by Application (2021-2026) Table 36. Global Drugs of UDCA Sales Market Share by Application (2027-2032) Table 37. Global Drugs of UDCA Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Drugs of UDCA Revenue by Application (2021-2026) & (k units) Table 39. Global Drugs of UDCA Revenue by Application (2027-2032) & (k units) Table 40. Global Drugs of UDCA Revenue Market Share by Application (2021-2026) Table 41. Global Drugs of UDCA Revenue Market Share by Application (2027-2032) Table 42. Global Drugs of UDCA Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Drugs of UDCA Sales by Region (2021-2026) & (k units) Table 44. Global Drugs of UDCA Sales Market Share by Region (2021-2026) Table 45. Global Drugs of UDCA Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Drugs of UDCA Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Drugs of UDCA Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Drugs of UDCA Sales by Country (2021-2026) & (k units) Table 49. North America Drugs of UDCA Sales by Country (2027-2032) & (k units) Table 50. Europe Drugs of UDCA Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Drugs of UDCA Sales by Country (2021-2026) & (k units) Table 52. Europe Drugs of UDCA Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Drugs of UDCA Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Drugs of UDCA Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Drugs of UDCA Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Drugs of UDCA Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Drugs of UDCA Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Drugs of UDCA Sales by Country (2027-2032) & (k units) Table 59. Global Drugs of UDCA Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Drugs of UDCA Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Drugs of UDCA Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Drugs of UDCA Revenue Market Share by Region (2021-2026) Table 63. Global Drugs of UDCA Revenue Market Share by Region (2027-2032) Table 64. Teva Company Information Table 65. Teva Business Overview Table 66. Teva Drugs of UDCA Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Teva Drugs of UDCA Product Portfolio Table 68. Teva Recent Development Table 69. Shanghai Pharma Company Information Table 70. Shanghai Pharma Business Overview Table 71. Shanghai Pharma Drugs of UDCA Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Shanghai Pharma Drugs of UDCA Product Portfolio Table 73. Shanghai Pharma Recent Development Table 74. Mylan Company Information Table 75. Mylan Business Overview Table 76. Mylan Drugs of UDCA Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Mylan Drugs of UDCA Product Portfolio Table 78. Mylan Recent Development Table 79. Mitsubishi Tanabe Pharma Company Information Table 80. Mitsubishi Tanabe Pharma Business Overview Table 81. Mitsubishi Tanabe Pharma Drugs of UDCA Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Mitsubishi Tanabe Pharma Drugs of UDCA Product Portfolio Table 83. Mitsubishi Tanabe Pharma Recent Development Table 84. Lannett Company Information Table 85. Lannett Business Overview Table 86. Lannett Drugs of UDCA Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Lannett Drugs of UDCA Product Portfolio Table 88. Lannett Recent Development Table 89. Impax Company Information Table 90. Impax Business Overview Table 91. Impax Drugs of UDCA Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Impax Drugs of UDCA Product Portfolio Table 93. Impax Recent Development Table 94. Grindeks Company Information Table 95. Grindeks Business Overview Table 96. Grindeks Drugs of UDCA Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Grindeks Drugs of UDCA Product Portfolio Table 98. Grindeks Recent Development Table 99. Epic Pharma Company Information Table 100. Epic Pharma Business Overview Table 101. Epic Pharma Drugs of UDCA Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Epic Pharma Drugs of UDCA Product Portfolio Table 103. Epic Pharma Recent Development Table 104. Dr. Falk Pharma Company Information Table 105. Dr. Falk Pharma Business Overview Table 106. Dr. Falk Pharma Drugs of UDCA Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Dr. Falk Pharma Drugs of UDCA Product Portfolio Table 108. Dr. Falk Pharma Recent Development Table 109. Daewoong Pharmaceutical Company Information Table 110. Daewoong Pharmaceutical Business Overview Table 111. Daewoong Pharmaceutical Drugs of UDCA Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Daewoong Pharmaceutical Drugs of UDCA Product Portfolio Table 113. Daewoong Pharmaceutical Recent Development Table 114. Bruschettini Company Information Table 115. Bruschettini Business Overview Table 116. Bruschettini Drugs of UDCA Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Bruschettini Drugs of UDCA Product Portfolio Table 118. Bruschettini Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Drugs of UDCA Distributors List Table 122. Drugs of UDCA Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Drugs of UDCA Product Image Figure 2. Global Drugs of UDCA Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs of UDCA Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs of UDCA Sales (2021-2032) & (k units) Figure 5. Global Drugs of UDCA Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Drugs of UDCA Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Capsule Image Figure 9. Tablet Image Figure 10. Global Drugs of UDCA Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Drugs of UDCA Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Drugs of UDCA Sales Market Share by Type (2021-2032) Figure 13. Global Drugs of UDCA Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Drugs of UDCA Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Drugs of UDCA Revenue Market Share by Type (2021-2032) Figure 16. Hepatopathy Image Figure 17. Gallstone Image Figure 18. Biliary Disease Image Figure 19. Other Image Figure 20. Global Drugs of UDCA Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Drugs of UDCA Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Drugs of UDCA Sales Market Share by Application (2021-2032) Figure 23. Global Drugs of UDCA Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Drugs of UDCA Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Drugs of UDCA Revenue Market Share by Application (2021-2032) Figure 26. North America Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Drugs of UDCA Sales Market Share by Country (2021-2032) Figure 28. U.S. Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Drugs of UDCA Sales Market Share by Country (2021-2032) Figure 33. Germany Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Drugs of UDCA Sales Market Share by Country (2021-2032) Figure 40. China Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Drugs of UDCA Sales Market Share by Country (2021-2032) Figure 48. Brazil Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Drugs of UDCA Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Drugs of UDCA Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Drugs of UDCA Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Drugs of UDCA Revenue (2021-2032) & (US$ Million) Figure 59. North America Drugs of UDCA Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Drugs of UDCA Revenue (2021-2032) & (US$ Million) Figure 61. Europe Drugs of UDCA Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Drugs of UDCA Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Drugs of UDCA Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Drugs of UDCA Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Drugs of UDCA Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Drugs of UDCA Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Drugs of UDCA Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Capsule
  • Tablet
Applications
  • Hepatopathy
  • Gallstone
  • Biliary Disease
  • Other
Companies covered
  • Teva
  • Shanghai Pharma
  • Mylan
  • Mitsubishi Tanabe Pharma
  • Lannett
  • Impax
  • Grindeks
  • Epic Pharma
  • Dr. Falk Pharma
  • Daewoong Pharmaceutical
  • Bruschettini

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drugs of UDCA Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drugs of UDCA Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Drugs of UDCA Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Drugs of UDCA Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Drugs of UDCA Market Dynamics
  1. 2.1 Drugs of UDCA Industry Trends
  2. 2.2 Drugs of UDCA Industry Drivers
  3. 2.3 Drugs of UDCA Industry Opportunities and Challenges
  4. 2.4 Drugs of UDCA Industry Restraints
3 Drugs of UDCA Market by Manufacturers
  1. 3.1 Global Drugs of UDCA Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Drugs of UDCA Sales by Manufacturers (2021-2026)
  3. 3.3 Global Drugs of UDCA Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Drugs of UDCA Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Drugs of UDCA Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Drugs of UDCA Manufacturers, Product Type & Application
  7. 3.7 Global Drugs of UDCA Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Drugs of UDCA Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Drugs of UDCA Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Drugs of UDCA Tier 1, Tier 2, and Tier 3
4 Drugs of UDCA Market by Type
  1. 4.1 Drugs of UDCA Type Introduction
  2. 4.1.1 Capsule
  3. 4.1.2 Tablet
  4. 4.2 Global Drugs of UDCA Sales by Type
  5. 4.2.1 Global Drugs of UDCA Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Drugs of UDCA Sales by Type (2021-2032)
  7. 4.2.3 Global Drugs of UDCA Sales Market Share by Type (2021-2032)
  8. 4.3 Global Drugs of UDCA Revenue by Type
  9. 4.3.1 Global Drugs of UDCA Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Drugs of UDCA Revenue by Type (2021-2032)
  11. 4.3.3 Global Drugs of UDCA Revenue Market Share by Type (2021-2032)
5 Drugs of UDCA Market by Application
  1. 5.1 Drugs of UDCA Application Introduction
  2. 5.1.1 Hepatopathy
  3. 5.1.2 Gallstone
  4. 5.1.3 Biliary Disease
  5. 5.1.4 Other
  6. 5.2 Global Drugs of UDCA Sales by Application
  7. 5.2.1 Global Drugs of UDCA Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Drugs of UDCA Sales by Application (2021-2032)
  9. 5.2.3 Global Drugs of UDCA Sales Market Share by Application (2021-2032)
  10. 5.3 Global Drugs of UDCA Revenue by Application
  11. 5.3.1 Global Drugs of UDCA Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Drugs of UDCA Revenue by Application (2021-2032)
  13. 5.3.3 Global Drugs of UDCA Revenue Market Share by Application (2021-2032)
6 Global Drugs of UDCA Sales by Region
  1. 6.1 Global Drugs of UDCA Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs of UDCA Sales by Region (2021-2032)
  3. 6.2.1 Global Drugs of UDCA Sales by Region (2021-2026)
  4. 6.2.2 Global Drugs of UDCA Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drugs of UDCA Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Drugs of UDCA Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Drugs of UDCA Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Drugs of UDCA Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Drugs of UDCA Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Drugs of UDCA Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Drugs of UDCA Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Drugs of UDCA Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Drugs of UDCA Revenue by Region
  1. 7.1 Global Drugs of UDCA Revenue by Region
  2. 7.1.1 Global Drugs of UDCA Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Drugs of UDCA Revenue by Region (2021-2026)
  4. 7.1.3 Global Drugs of UDCA Revenue by Region (2027-2032)
  5. 7.1.4 Global Drugs of UDCA Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Drugs of UDCA Revenue (2021-2032)
  8. 7.2.2 North America Drugs of UDCA Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Drugs of UDCA Revenue (2021-2032)
  11. 7.3.2 Europe Drugs of UDCA Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Drugs of UDCA Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Drugs of UDCA Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Drugs of UDCA Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Drugs of UDCA Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Drugs of UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Drugs of UDCA Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Shanghai Pharma
  8. 8.2.1 Shanghai Pharma Company Information
  9. 8.2.2 Shanghai Pharma Business Overview
  10. 8.2.3 Shanghai Pharma Drugs of UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Shanghai Pharma Drugs of UDCA Product Portfolio
  12. 8.2.5 Shanghai Pharma Recent Developments
  13. 8.3 Mylan
  14. 8.3.1 Mylan Company Information
  15. 8.3.2 Mylan Business Overview
  16. 8.3.3 Mylan Drugs of UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Mylan Drugs of UDCA Product Portfolio
  18. 8.3.5 Mylan Recent Developments
  19. 8.4 Mitsubishi Tanabe Pharma
  20. 8.4.1 Mitsubishi Tanabe Pharma Company Information
  21. 8.4.2 Mitsubishi Tanabe Pharma Business Overview
  22. 8.4.3 Mitsubishi Tanabe Pharma Drugs of UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mitsubishi Tanabe Pharma Drugs of UDCA Product Portfolio
  24. 8.4.5 Mitsubishi Tanabe Pharma Recent Developments
  25. 8.5 Lannett
  26. 8.5.1 Lannett Company Information
  27. 8.5.2 Lannett Business Overview
  28. 8.5.3 Lannett Drugs of UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Lannett Drugs of UDCA Product Portfolio
  30. 8.5.5 Lannett Recent Developments
  31. 8.6 Impax
  32. 8.6.1 Impax Company Information
  33. 8.6.2 Impax Business Overview
  34. 8.6.3 Impax Drugs of UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Impax Drugs of UDCA Product Portfolio
  36. 8.6.5 Impax Recent Developments
  37. 8.7 Grindeks
  38. 8.7.1 Grindeks Company Information
  39. 8.7.2 Grindeks Business Overview
  40. 8.7.3 Grindeks Drugs of UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Grindeks Drugs of UDCA Product Portfolio
  42. 8.7.5 Grindeks Recent Developments
  43. 8.8 Epic Pharma
  44. 8.8.1 Epic Pharma Company Information
  45. 8.8.2 Epic Pharma Business Overview
  46. 8.8.3 Epic Pharma Drugs of UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Epic Pharma Drugs of UDCA Product Portfolio
  48. 8.8.5 Epic Pharma Recent Developments
  49. 8.9 Dr. Falk Pharma
  50. 8.9.1 Dr. Falk Pharma Company Information
  51. 8.9.2 Dr. Falk Pharma Business Overview
  52. 8.9.3 Dr. Falk Pharma Drugs of UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Dr. Falk Pharma Drugs of UDCA Product Portfolio
  54. 8.9.5 Dr. Falk Pharma Recent Developments
  55. 8.10 Daewoong Pharmaceutical
  56. 8.10.1 Daewoong Pharmaceutical Company Information
  57. 8.10.2 Daewoong Pharmaceutical Business Overview
  58. 8.10.3 Daewoong Pharmaceutical Drugs of UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Daewoong Pharmaceutical Drugs of UDCA Product Portfolio
  60. 8.10.5 Daewoong Pharmaceutical Recent Developments
  61. 8.11 Bruschettini
  62. 8.11.1 Bruschettini Company Information
  63. 8.11.2 Bruschettini Business Overview
  64. 8.11.3 Bruschettini Drugs of UDCA Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bruschettini Drugs of UDCA Product Portfolio
  66. 8.11.5 Bruschettini Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Drugs of UDCA Value Chain Analysis
  2. 9.1.1 Drugs of UDCA Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Drugs of UDCA Production Mode & Process
  6. 9.2 Drugs of UDCA Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Drugs of UDCA Distributors
  9. 9.2.3 Drugs of UDCA Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst